INTRODUCTION

During the short period of approximately 3 months since coronavirus disease 2019 (COVID-19) was first reported in the city of Wuhan, Hubei Province, China at the end of December 2019, this disease became a pandemic, with large-scale outbreaks in China, South Korea, Iran, and Europe [1-4]. Although the World
Health Organization declared COVID-19 to be a public health emergency of international concern on January 30, 2020 [5], the number of patients diagnosed with COVID-19 in Europe, the United States, and South America exploded in March 2020 [6,7]. The reproductive number of COVID-19 estimated from previous studies varies; promisingly, chest computed tomography (CT) has been investigated; additionally, chest computed tomography (CT) has recently been reported to detect lung changes caused by COVID-19 [8].

COVID-19 is mainly diagnosed by using real-time reverse transcription-polymerase chain reaction (rRT-PCR) to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in samples obtained through nasopharyngeal or oropharyngeal swabs [10-13]. Although rRT-PCR for COVID-19 was initially developed within 2 weeks after the emergence of the disease, this test cannot be performed on all suspected patients because COVID-19 has rapidly spread beyond the capacity for testing [14]. Thus, proper screening for the disease and isolation of suspected patients performed by the physicians and healthcare providers who first come into contact with them is the most important step in controlling this highly infectious disease, meaning that awareness and knowledge of the clinical features of COVID-19 are necessary for physicians and healthcare providers [15]. The most common symptom in patients diagnosed with COVID-19 is known to be fever, which is frequently accompanied by coughing or difficulty in breathing [16,17]. However, some COVID-19 patients demonstrate no symptoms or complain of only gastrointestinal (GI) symptoms; furthermore, the clinical features of COVID-19 patients diagnosed outside of Wuhan, China differed from those of patients diagnosed in Wuhan [18]. Therefore, additional diagnostic clues for COVID-19 have been investigated; promisingly, chest computed tomography (CT) has recently been reported to detect lung changes caused by COVID-19 before the occurrence of symptoms [19,20].

Within only 2 months since the first report of COVID-19, hundreds of reports related to COVID-19 have been published in reputable scientific journals. At this point, it is impossible to conduct a randomized clinical trial or a well-designed prospective study on the diagnosis and treatment of COVID-19, as only a short time has passed since this new disease emerged. Proportion meta-analysis is a statistical technique that provides integrated information in the absence of studies with a high level of evidence [21-24]. It should be kept in mind that this technique provides a relatively low level of evidence compared to other types of meta-analysis, as it generates results from studies with low levels of evidence, such as case series or observational studies [23]. However, this technique is expected to provide more integrated information about COVID-19 for health-care providers than is provided by extant studies in isolation.

Since the first report in Wuhan, the medical environment surrounding COVID-19 has undergone many changes, including increased awareness of the disease and the dissemination of diagnostic kits. Thus, it is expected that there will be changes in the clinical features of patients diagnosed with COVID-19, and identifying such differences will help health-care providers better understand and diagnose this disease. The objectives of this study were to identify the clinical features and chest CT findings of COVID-19 patients and to compare the characteristics of patients diagnosed in Wuhan and in other areas by integrating the findings reported in previous studies.

**MATERIALS AND METHODS**

Protocol of the study
This study was conducted under the recommendations of Reporting Items for Systematic Reviews and Meta-Analyses. This study was performed by two teams for rapid review, one team was in charge of the survey and collection of included studies, and the other team was in charge of quality assessment of the included studies. Each team consisted of two main reviewers and a supervisor who adjusted the disagreements of the review results. For rapid review considering the urgency of a target disease for analysis, all types of the article what identified in the online databases were considered as candidates for inclusion in the study.

Survey of literature and inclusion of studies for analysis
On March 17, 2020, two reviewers (YSL and WJ) searched the online databases of the U.S. National Library of Medicine (Medline) and Excerpta Medica (Embase) for identifying reports published in English that used the terms: COVID-19; SARS-Cov-2; and Novel coronavirus 2019. The titles, abstracts, and authors’ information were saved into excel files, and later screened by two reviewers. All type of reports in the English language that contained the descriptions of clinical features and CT findings except for the review articles were included in a data-set for detailed review, and two reviewers included only studies with data on four or more patients (case-series, cohort, or observational study) into the data-set to provide a higher level of evidence.
Published editorials and letters to editors were also considered as candidates for the study to a maximum extent possible. In the review process (the assessments of study eligibility), to minimize the risk of duplicating data in this analysis [26], only the largest study was included if the duration of patient inclusion overlapped among reports from the same hospital. If data were reported from the same hospital without information about the date of patient inclusion, this study was also eventually excluded. All data were collected using identical forms to minimize the variability of reviewers, and disagreements of in the review results were adjusted by the third reviewer (JL).

Data collection and quality assessment
The extraction of data from included studies was independently conducted by two reviewers. Name of the first author, the origin of reports including hospital and province, the initial date of patient inclusion, and the number of patients included were recorded in the Microsoft Excel database. Demographic data, symptoms of patients, and chest CT findings were extracted. The results were categorized into the regions where COVID-19 patients were diagnosed as follows: Wuhan, outside of Wuhan in China, and other country groups. Quality assessments of included studies were independently performed by two reviewers (professors of college of medicine, CGC and SWP), who did not participate in the data review process, using a quality assessment tool for case-series study from the National Institutes of Health, which consisted of nine questions (Supplementary Table 1) [27]. The disagreements in the quality assessment were also discussed by a third reviewer (JL). The results of the quality assessment were represented in a fair, good, and poor grouping to assist in the understanding of this study.

Statistical analysis
Proportion meta-analysis was conducted to determine the clinical features and chest CT findings of COVID-19 patients; subsequently, clinical and chest CT characteristics of patients were compared after the areas diagnosed with COVID-19 were classified as Wuhan, outside of Wuhan in China, and other countries. We used a random-effect model provided by MedCalc statistical software due to the presence of uncontrolled variables of included studies. All results were represented as a forest plot with the horizontal bar corresponding to the 95% confidence interval (CI) of the effect estimates, and overlap of 95% CI was defined as the absence of difference among the groups in the comparative analysis [28]. F test and Cochran Q were used for evaluating heterogeneities of the results belonging to analysis. F lied between 0% to 100% and additional descriptions were made if they complied with the criteria described as follows: low (<40%), moderate (30%–60%), and considerable (75%–100%), retrospectively [29]. This parameter stated the percentage of variability in effect estimates calculated from heterogeneity. Cochran Q test is the parameter computed by summing squared deviations of the estimate of each study, and the parameter of <0.10 determined the heterogeneity [30]. Although we described these two parameters for measuring heterogeneity, F which is not affected by the number of included studies for meta-analysis was considered as a more appropriate parameter for the evaluation of heterogeneity in this study [30]. The publication bias among included studies was determined when the P-value was <0.05 on Egger’s regression test [31]. Forest plot calculated by MedCalc was redrawn using Microsoft Excel program (Microsoft, Redmond, WA, USA) for easy interpretation of figure [32]. Chi-square test was used to compare the compositions of gender among groups.

Fig. 1. Flowchart of the final inclusion of studies. Nine studies were found to be eligible for the meta-analysis [33-41], extracted from 783 abstracts and titles.
RESULTS

Data extraction from included studies and quality assessment

In total, 783 abstracts and titles were identified and screened, and 102 abstracts were excluded in this step as they were not written in English. Additionally, abstracts presenting clinical features and chest CT findings from four or fewer patients were excluded. Eighty-seven reports were completely reviewed, and studies that were likely to present duplicate patient data were also excluded. Finally, nine studies (four studies reporting findings from Wuhan and five studies reporting findings from outside of Wuhan in China) with level IV evidence (case series, observational studies, or cohort studies) were eligible for the meta-analysis (Fig. 1) [33-41]. As only one study each from South Korea and Europe described the clinical features and chest CT findings of patients from outside China, a comparative analysis was only possible between patients diagnosed in Wuhan and outside of Wuhan in China. Information about 627 patients (male, 345; female, 282) diagnosed with COVID-19 was obtained from nine studies (Table 1). However, it was not possible to consistently present the mean or median age of the included patients because five studies reported age as a median value and four studies reported age as a mean value. There was no significant difference in the sex ratio between the two groups (P=0.157) upon chi-square analysis. Among the clinical features described in the included studies, fever, cough, sputum, dyspnea, myalgia, fatigue, and GI symptoms were available for meta-analysis and comparisons (Table 2). Comparisons of chest CT findings were possible for pathologic findings (ground-glass opacity [GGO] and consolidation) and the distribution of abnormal findings (single lobe, multiple lobes, and both lungs) (Table 3). Laboratory findings (leukocytosis, leukopenia, and decreased lymphocyte count) could also be analyzed, as demonstrated in Supplementary Table 2.

Clinical features

COVID-19 was diagnosed despite the absence of symptoms in 4.1% of the patients (9/242) from outside of Wuhan (Table 2). Fever (84.8%; 95% CI, 78.5% to 90.1%; I²=73.6%) was the most common symptom of COVID-19, followed by cough (52.0%; 95% CI, 34.1% to 69.7%; I²=95.0%) (Fig. 2A and B). Sputum and dyspnea were only present in 21.3% (95% CI, 17.2% to 25.7%; I²=0%) and 10.4% (95% CI, 2.0% to 24.5%; I²=88.8%) of patients, respectively (Fig. 2C). Myalgia and fatigue were present in 27.3% (95% CI, 16.6% to 39.4%; I²=87.6%) and 16.7% (95% CI, 10.4% to 24.2%; I²=72.5%) of patients, respectively. GI symptoms were reported by 11.6% (95% CI, 7.7% to 16.1%; I²=54.6%) of patients (Fig. 2D).

In a comparison of symptoms between the patients diagnosed in Wuhan and outside of Wuhan, fever was more frequently observed in the patients diagnosed in Wuhan (91.7%; 95% CI, 88.0% to 94.8%; I²=17.94%) than in those diagnosed outside of Wuhan (78.1%; 95% CI, 73.2% to 82.7%; I²=0%) (Fig. 3A).
### Table 2. The proportions of clinical features of the included subjects

| First author  | Age (range, yr) | Sex (M:F) | No. of patients | Fever | Cough | Sputum | Dyspnea | Myalgia | Sore throat | Headache | Fatigue |
|---------------|----------------|-----------|----------------|-------|-------|--------|---------|---------|-------------|----------|---------|
| **Wuhan**     |                |           |                |       |       |        |         |         |             |          |         |
| Zhou [33]     | Median, 56.0 (46–57) | 119:72 | 191           | 180 (94.2) | 151 (79.0) | 44 (23.0) | 29 (15.2) | 16 (8.3) | 44 (23.0) |
| Zhou [34]     | Mean, 52.8 (30–77)  | 39:23   | 62            | 54 (87.1)  | 28 (45.2)  | 15 (24.2) | 20 (32.2) | 9 (14.5) | 14 (22.6) |
| Li [35]       | Mean, 58.0 (26–83)  | 28:23   | 51            | 46 (90.2)  | 1 (2.0)  | 1 (2.0)  |         |         |            | 3 (5.9)  |
| Huang [36]    | Mean, 56.0 (26–88)  | 14:20   | 34            | 32 (94.1)  | 17 (30)  | 8 (23.5) | 5 (14.7) | 22 (64.7) | 2 (5.9)  | 5 (14.7) |
| **Total**     |                |           | 200:138       | 1/51 (2.0) | 312/338 (94.2) | 197/338 (58.3) | 52/225 (23.1) | 20/96 (20.8) | 71/287 (24.7) | 234/597 (39.4) |
| **Outside of Wuhan** |          |           |                |       |       |        |         |         |             |          |         |
| Liu [37]      | Median, 42 (34–50) | 46:10   | 10            | 7 (70.0)  | 8 (80.0)  |        | 4 (40.0) | 3 (30.0) | 3 (30.0)  |          |         |
| Liu [38]      | NA            | 31:25   | 56            | 44 (78.6)  | 21 (35.7) | 4 (7.1)  |        |        | 10 (17.9) | 5 (8.9)  |         |
| Zhu [39]      | Median, 46 (35–52) | 15:17 | 32            | 27 (84.4)  | 21 (66.6) | 5 (15.6) | 5 (15.6) | 1 (31)  | 1 (31)    |          |         |
| Zhao [40]     | Mean, 44.4 (17–75) | 56:45 | 101           | 2 (2.1)  | 79 (78.2) | 63 (62.4) | 1 (1.0)  | 17 (16.8) | 12 (11.9) | 5 (5.0)  |         |
| Xu [41]       | Median, 50 (18–86) | 39:51 | 90            | 6 (6.7)  | 70 (77.8) | 57 (63.3) | 11 (12.2) | 25 (27.8) | 23 (25.6) | 4 (4.4)  | 12 (13.3) | 19 (21.1) |
| **Total**     |                |           | 145:144       | 8/191 (4.2) | 227/289 (78.5) | 170/289 (58.8) | 16/122 (13.1) | 5/157 (6.3) | 47/223 (21.1) | 39/201 (19.4) | 8/132 (6.1) | 31/289 (10.7) | 24/146 (16.4) |
| **Total**     |                |           | 345:282       | 9/242 (4.1) | 539/627 (86.0) | 367/627 (58.5) | 68/347 (19.6) | 25/253 (9.9) | 118/510 (22.9) | 39/201 (19.4) | 10/166 (6.0) | 61/576 (10.6) | 85/450 (18.9) |

GI, gastrointestinal; NA, not applicable.

### Table 3. The proportions of pathologic patterns and their distributions on chest computed tomography of the included subjects

| First author  | No. of patients | Pathologic pattern | Distribution |
|---------------|----------------|--------------------|--------------|
|               |                | GGO                | Consolidation | Single lobe | Multiple lobe | Both lungs |
| **Wuhan**     |                |                    |              |            |              |            |
| Zhou [33]     | 191           | 136 (71.2)         | 112 (58.6)   | 143 (74.8) |
| Zhou [34]     | 62            | 25 (40.3)          | 21 (33.8)    | 52 (83.8)  | 52 (83.9)  |
| Li [35]       | 51            | 46 (90.2)          | 21 (41.1)    | 3 (5.9)    | 48 (94.1)  | 48 (94.1)  |
| Huang [36]    | 34            | 3 (8.8)            |              |            |            | 27 (79.4)  |
| **Total**     | 338           | 207/304 (68.1)     | 154/304 (50.6)| 16/147 (10.8)| 100/113 (88.5)| 270/338 (79.9)|
| **Outside of Wuhan** |           |                    |              |            |              |            |
| Liu [37]      | 10            | 4 (40.0)           | 5 (50.0)     |            |            |            |
| Liu [38]      | 56            |                    |              |            |            |            |
| Zhu [39]      | 32            | 15 (46.9)          | 4 (12.5)     | 1 (3.1)    | 29 (90.6)  | 29 (90.6)  |
| Zhao [40]     | 101           | 87 (86.1)          | 44 (43.6)    | 6 (5.9)    | 87 (86.1)  | 83 (82.1)  |
| Xu [41]       | 90            | 65 (72.2)          | 12 (13.3)    | 12 (13.3)  | 53 (58.9)  | 53 (58.8)  |
| **Total**     | 289           | 171/233 (73.3)     | 65/233 (27.9)| 53/279 (19.0)| 209/279 (74.9)| 165/223 (74.0)|
| **Total**     | 627           | 378/537 (66.8)     | 219/537 (40.8)| 383/561 (68)| 309/392 (78.8)| 435/561 (77.5)|

Values are presented as number (%).

GGO, ground-glass opacity.
However, the proportion of patients with cough was similar between the Wuhan (41.3%; 95% CI, 8.2% to 79.9%; I² = 97.9%) and non-Wuhan groups (59.4%; 95% CI, 47.8% to 70.4%; I² = 71.2%). Similar to fever, dyspnea was significantly more frequent in the patients diagnosed in Wuhan (21.1%; 95% CI, 13.2% to 30.3%; I² = 11.0%) than in those diagnosed outside of Wuhan (3.80%; 95% CI, 0.13% to 12.22%; I² = 74.75%) (Fig. 3B). However, no significant difference was observed in the frequency of sputum between the Wuhan group (23.3%; 95% CI, 18.1% to 29.1%; I² = 0%) and the non-Wuhan group (17.7%; 95% CI, 11.5% to 24.9%; I² = 0%).

**Chest CT findings**

The chest CT findings of the included studies are presented in Table 3. A GGO pattern and consolidation were observed in 66.76% (95% CI, 52.56% to 79.55%; I² = 90.35%) and 35.15% (95% CI, 20.96% to 50.84%; I² = 92.02%) of COVID-19 patients, respectively (Fig. 4). The most common distribution of pathologic findings was involvement of multiple lobes (81.21%; 95% CI, 69.73% to 90.46%; I² = 81.84%), while only 14.47% (95% CI, 4.99% to 28.27%; I² = 91.82%) of patients had pathologic findings distributed in a single lobe (Fig. 5). Bilateral lung involvement was identified in 80.41% (95% CI, 71.75% to 87.81%; I² = 81.84%) of patients. No significant difference was observed in the frequency of patients in whom the pathologic findings showed only single-lobe involvement between the Wuhan group (11.09%; 95% CI, 5.71% to 17.96%; I² = 32.20%) and the non-Wuhan group (17.77%; 95% CI, 2.22% to 43.56%;
The distribution of multiple-lobe and bilateral lung involvement was similar in both groups. The results of the comparison of the proportions of chest CT findings between the groups are presented in Supplementary Figs. 1 and 2.

**DISCUSSION**

Within only 3 months after it was first reported in China, the COVID-19 pandemic has spread to South Korea, Iran, Italy, and the United States, and the number of patients worldwide has rapidly increased [6,7]. Since COVID-19 is estimated to be more
Clinical and Experimental Otorhinolaryngology  Vol. 13, No. 2: 95-105, May 2020

infectious than MERS and more fatal than influenza, physicians and health-care providers should actively work to diagnose CO-
VID-19 and to keep COVID-19 patients in isolation to minimize
the spread of the disease and prevent deterioration of the cur-
current situation. Although COVID-19 is diagnosed using rRT-PCR
tests, proper screening conducted by health-care providers is the
most important prerequisite for controlling the spread of COV-
ID-19, as diagnostic capacity and accessibility of medical care
differ from country to country [15,42].

Patients’ symptoms are important clues for the diagnosis of a
disease, and the same is true for the screening of diseases [15].
Essentially, all the relevant guidelines recommend that symptoms
and epidemiological risk (history of contact with COVID-19 pa-
tients and history of visits to pandemic-affected areas) should be
considered as part of COVID-19 screening [7,12,43,44]. Accord-
ing to the Centers for Disease Control and Prevention, screening
for COVID-19 should be based on the presence of symptoms of
fever, cough, and shortness of breath [12]. The most common
symptom in patients diagnosed with COVID-19 was fever (84.8%;
95% CI, 78.5% to 90.1%; \( r^2 = 73.6 \)%), which was frequently
accompanied by cough (52.0%; 95% CI, 34.1% to 69.7%; \( r =
95.0 \)%). In addition, 21.3% and 10.4% of patients complained
of sputum and dyspnea (other signs of respiratory infection).

Moreover, myalgia (27.3%) and fatigue (16.7%), which are symp-
toms of inflammation due to SARS-CoV-2, were also less com-
mon than fever and cough. Although all of symptoms mentioned
above, except sputum, exhibited significant heterogeneity, fever
accompanied by the signs of a respiratory infection can be con-
sidered as a reasonable parameter for suspecting COVID-19, es-
specially in patients with epidemiological risk, as has been rec-
commended by many guidelines [7,12,43,44]. Interestingly, over
10% of patients in the present study complained of GI symp-
toms. GI symptoms are thought to be a characteristic of SARS-
CoV-2 infection, especially in light of the previous finding that
over 30% of MERS patients complained of GI symptoms [45].

Recently, olfactory and gustatory dysfunction as determined by
a questionnaire evaluation has been observed in 85% of mild-
to-moderate COVID-19 patients in Europe; the reported frequen-
cy of this symptom is therefore similar to that of fever and high-
ger than that of cough in the present study [46]. Thus, physicians,
especially otorhinolaryngologists, should be aware of these symp-
toms, in addition to fever accompanied by the signs of respirato-
ry infection, as a possible clinical presentation of COVID-19. Olf-
actory and gustatory complaints were the initial symptoms in
approximately 15% of COVID-19 patients, and 11.8% of pa-
tients complained of only olfactory changes without other nasal
symptoms [46]. However, we could not find any information on these symptoms in the studies included in this meta-analysis. The patients included in this study were mainly diagnosed with COVID-19 in January 2020, not long after the emergence of COVID-19. Since these diagnoses were made in the early phase of COVID-19 transmission, a lack of awareness of olfactory/gustatory dysfunction, as well as differences in disease severity in patients depending on the time of COVID-19 diagnosis, may explain why information on these symptoms was missing in the included studies. Although the results of this study did not address olfactory or gustatory dysfunctions observed in COVID-19 patients, based on current knowledge, otorhinolaryngologists must consider the possibility of COVID-19 if patients with epidemiological risk of this disease complain of olfactory or gustatory dysfunction.

Fever is known to occur in a relatively early phase of COVID-19, whereas dyspnea is a symptom that generally occurs in the rapid progression phase, which takes place 3 to 7 days after the onset of symptoms [44]. The present meta-analysis revealed that fever and dyspnea were less frequent in the patients diagnosed outside of Wuhan than in those diagnosed in Wuhan. In addition, asymptomatic COVID-19 patients were only reported in the non-Wuhan group. In a report from South Korea, among a total of 28 patients, three patients without symptoms (10.71%) were diagnosed with COVID-19, and only 32.14% of patients (9/28) complained of fever [47]. This trend was also observed in a study reporting the clinical features of 38 COVID-19 patients in Europe; 5.26% of patients (2/38) were asymptomatic and fever was observed in only 52.63% (20/38) [48]. Most studies of both groups (the Wuhan group and the non-Wuhan group) in this meta-analysis included patients diagnosed in a similar period. Since the initial outbreak of COVID-19 is assumed to have occurred in Wuhan, the interval between infection and COVID-19 diagnosis is thought to have been shorter in the non-Wuhan group than in the Wuhan group. Thus, the lower frequency of fever and the higher number of asymptomatic patients observed outside of Wuhan is thought to be due to the early diagnosis of COVID-19 as a consequence of physicians’ increased awareness of the disease and epidemiological assessments of high-risk individuals. Although it was not practicable to conduct a meta-regression analysis of the effect of age on clinical manifestations because of variation in how age was reported in the included studies, the patients from outside of Wuhan seemed to be younger than the patients diagnosed in Wuhan. Since the clinical manifestations and disease severity of COVID-19 vary depending on age [38], these results should be interpreted with caution, in light of the possibility that the age difference between the groups may have affected the differences in clinical manifestations found in this study.

Regarding disease screening, we still should be aware that fever and dyspnea were less frequent in patients diagnosed outside of Wuhan in China. It is apparent that only using symptoms as screening criteria for COVID-19 results in an increased chance of failure of early diagnosis of COVID-19 in actual patients. Therefore, the assessment of epidemiological risk is of prime importance in patients complaining of fever accompanied by signs of respiratory infection. If it is not possible to conduct rRT-PCR for COVID-19 in high-risk individuals, proper isolation of these patients for 2 weeks to minimize their contact with other people around them—even if they do not have symptoms or their symptoms are minor—is necessary considering the incubation period of COVID-19 [43]. In addition, it would be preferable to have a monitoring system for identifying patients’ history of visits to pandemic-affected areas and for keeping track of high-risk individuals through government interventions with the purpose of controlling this infectious disease.

Numerous studies have reported the radiologic findings of COVID-19 patients. While simple chest radiography plays a limited role in COVID-19 screening, chest CT is known to detect lung abnormalities, single or focal GGO patterns, the presence of a nodule in the central lobule, and patchy consolidation even before the onset of symptoms because of its high resolution [34,40,44]. GGO is an initial pathologic finding that can be observed in the lungs even before symptom onset, whereas the consolidation pattern is a relatively late finding in the progression of COVID-19 [44]. These pathologic findings gradually involve bilateral and multiple lobes during the course of disease progression. Although we assumed that COVID-19 was diagnosed earlier in the non-Wuhan group, no significant between-group differences were found in the distribution of patterns involving a single lobe, multiple lobes, and the bilateral lungs. The results regarding GGO and consolidation are similar to results reported from South Korea (GGO, 8/9; consolidation, 2/9) [49]. Since all five parameters reflecting chest CT findings exhibited considerable heterogeneity in the results extracted from the included studies, the present study does not provide support for any conclusions regarding the role of chest CT in COVID-19 screening.

This study has several limitations and the results should be interpreted with caution. First, the results of this study can only serve as the basis for weak recommendations because of the low level of evidence of the included studies, the small number of patients, and methodological limitations [24]. Second, there was considerable heterogeneity in the results of the included studies. It is hypothesized that these outcomes could reflect differences between the groups. Third, it is possible that this study did not include exhaustive information about COVID-19, as case reports and studies with insufficient information were excluded from the present analysis to increase the level of evidence.

In conclusion, fever accompanied by signs of respiratory infection is considered to be the most reliable manifestation of COVID-19. Fever and dyspnea were observed less frequently in patients diagnosed outside of Wuhan in China, which should be considered in COVID-19 screening. Regional differences in the
proportion of symptoms may be attributable to the earlier diagnosis of the disease and the younger age of the patients outside of Wuhan although further analysis is needed. Finally, the results of this study do not support any specific conclusions regarding the role of chest CT in diagnosing COVID-19.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ORCID

Joo-Hyun Park https://orcid.org/0000-0002-1499-3328
Wook Jang https://orcid.org/0000-0003-2748-2524
Sang-Woo Kim https://orcid.org/0000-0003-0011-0552
Jeongjun Lee https://orcid.org/0000-0001-6847-1130
Yun-Sung Lim https://orcid.org/0000-0002-5997-6193
Chang-Gun Cho https://orcid.org/0000-0002-7103-8896
Seok-Won Park https://orcid.org/0000-0003-4262-2150
Bo Hae Kim https://orcid.org/0000-0002-4645-0678

AUTHOR CONTRIBUTIONS

Conception: BHK. Data curation: WJ, JL, YSL, CGC, SWP. Formal analysis: BHK, SWK. Writing - original draft: JHP, BHK. Writing - review & editing: all authors.

SUPPLEMENTARY MATERIALS

Supplementary materials can be found via https://doi.org/10.21053/ceo.2020.00570.

REFERENCES

1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020 Apr;92(4):401-2.
2. Shim E, Tariq A, Choi W, Lee Y, Chowell G. Transmission potential and severity of COVID-19 in South Korea. Int J Infect Dis. 2020 Mar;93:339-44.
3. Tuite AR, Bogoch II, Sherbo R, Watts A, Fisman D, Khan K. Estimation of coronavirus disease 2019 (COVID-19) burden and potential for international dissemination of infection from Iran. Ann Intern Med. 2020 Mar 16 [Epub]. https://doi.org/10.7326/M20-0696.
4. Saglietto A, D’Ascenzo F, Zoccai GB, De Ferrari GM. COVID-19 in Europe: the Italian lesson. Lancet. 2020 Apr;395(10230):1110-1.
5. World Health Organization. Novel coronavirus (2019-nCoV) situation report-10 [Internet]. Geneva, CH: World Health Organization; 2020 [cited 2020 Apr 22]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200128-sitrep-10ncov.pdf?sfvrsn=d0b2e480.
6. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report-67 [Internet]. Geneva, CH: World Health Organization; 2020 [cited 2020 Apr 22]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200327-sitrep-67-covid-19.pdf?sfvrsn=b65f68eb.
7. Eurosurveillance Editorial Team. Updated rapid risk assessment from ECDC on the novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK. Euro Surveill. 2020 Mar;25(10):2003121.
8. Liu Y, Gayle AA, Wilder-Smith A, Rocklov J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020 Mar;27(2):taaa021.
9. Callaway E, Cynomoski D, Mallapaty S, Stoye E, Tollefson J. The coronavirus pandemic in five powerful charts. Nature. 2020 Mar;579(7800):482-3.
10. Peng L, Liu J, Xu W, Luo Q, Deng K, Lin B, et al. 2019 Novel coronavirus can be detected in urine, blood, anal swabs and oropharyngeal swabs samples [Internet]. medRxiv; 2020 [cited 2020 Apr 21]. Available from: https://doi.org/10.1101/2020.02.21.20026179.
11. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020 Jan;25(3):200045.
12. Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID-19) in healthcare settings [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 2020 [cited 2020 Apr 22]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html.
13. World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases [Internet]. Geneva, CH: World Health Organization; 2020 [cited 2020 Apr 22]. Available from: https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117.
14. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med. 2020 Mar 19 [Epub]. https://doi.org/10.1515/cclm-2020-0240.
15. World Health Organization. Controlling the spread of infectious disease. In: Magnusson R, editor. Advancing the right to health: the vital role of law. Geneva, CH: World Health Organization; 2016. p. 151-64.
16. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-Pena R, Holguin-Rivera Y, Escalera-Antezena JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar 13 [Epub]. https://doi.org/10.1016/j.tmaid.2020.101623.
17. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. J Med Virol. 2020 Mar;92(10):1515-64.
18. Xu WW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020 Feb;368:m606.
19. Kim JY, Chee PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures. J Korean Med Sci. 2020 Feb;35(5):e61.
20. Pan Y, Guan H, Zhan S, Wang Y, Li Q, Zhu T, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur
36. Huang Y, Tu M, Wang S, Chen S, Zhou W, Chen D, et al. Clinical characteristics of laboratory-confirmed cases of COVID-19 pneumonia in Wuhan, China: a retrospective single center analysis. Travel Med Infect Dis. 2020 Feb 27 [Epub]. https://doi.org/10.1016/j.tmaid.2020.101606.

37. Liu F, XuA, Zhang Y, Xuan W, Yan T, Pan K, et al. Patients of COVID-19 may benefit from sustained lopinavir/ritonavir combination and the increase of osimipravir may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020 Mar 6 [Epub]. https://doi.org/10.1016/j.ijid.2020.03.013.

38. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020 Mar 11 [Epub]. https://doi.org/10.1016/j.jinf.2020.03.005.

39. Zhu W, Xie K, Lu H, Xu L, Zhou S, Fang S. Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China. J Med Virol. 2020 Mar 13 [Epub]. https://doi.org/10.1002/jmv.25763.

40. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study. AJR Am J Roentgenol. 2020 Mar [Epub]. https://doi.org/10.2214/AJR.20.22976.

41. Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging. 2020 May;47(5):1275-80.

42. Quinn SC, Kumar S. Health inequalities and infectious disease epidemics: a challenge for global health security. Biosecur Bioterror. 2014 Sep-Oct;12(5):263-73.

43. Central Accident Investigation Headquarters. Korean Government’s Response System [Internet]. Sejong, KR: Central Accident Investigation Headquarters; 2020 [cited 2020 Apr 22]. Available from: http://ncov.mohw.go.kr/er/baroView.do?brdId=11&brdGubun=111&data=005&ncvContSeq=&contSeq=&board_id.

44. Jian YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020 Feb;7(1):4.

45. Arabi YM, Balkhy HH, Hayden FG, Bouchama A, Luke T, Baillie JK, et al. Middle East respiratory syndrome. N Engl J Med. 2017 Feb;376(6):584-94.

46. Lechner JR, Chiesa-Estomba CM, De Sisti DR, Horoi M, Lee Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020 Apr 6 [Epub]. https://doi.org/10.1007/s00405-020-05965-1.

47. COVID-19 National Emergency Response Center, Epidemiology and Case Management Team, Korea Centers for Disease Control and Prevention. Early epidemiological and clinical characteristics of 28 cases of coronavirus disease in South Korea. Osong Public Health Res Perspect. 2020 Feb;11(1):8-14.

48. Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill. 2020 Mar;25(9):2000178.

49. Yoon SH, Lee KH, Kim JY, Lee YK, Ko H, Kim KH, et al. Chest radiographic and CT findings of the 2019 novel coronavirus disease (COVID-19): analysis of nine patients treated in Korea. Korean J Radiol. 2020 Apr;21(4):494-500.